JP2019508481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508481A5 JP2019508481A5 JP2018550872A JP2018550872A JP2019508481A5 JP 2019508481 A5 JP2019508481 A5 JP 2019508481A5 JP 2018550872 A JP2018550872 A JP 2018550872A JP 2018550872 A JP2018550872 A JP 2018550872A JP 2019508481 A5 JP2019508481 A5 JP 2019508481A5
- Authority
- JP
- Japan
- Prior art keywords
- dccpm
- peptide
- amino acids
- cpa
- bac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 230000001588 bifunctional effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 9
- 239000000074 antisense oligonucleotide Substances 0.000 claims 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims 4
- 230000007935 neutral effect Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- RTIIDBURLHHYRK-ZETCQYMHSA-N (2S)-2-(pent-1-enylamino)propanoic acid Chemical compound CCCC=CN[C@@H](C)C(O)=O RTIIDBURLHHYRK-ZETCQYMHSA-N 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000018360 neuromuscular disease Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- RTIIDBURLHHYRK-SSDOTTSWSA-N C(=CCCC)N[C@H](C)C(=O)O Chemical compound C(=CCCC)N[C@H](C)C(=O)O RTIIDBURLHHYRK-SSDOTTSWSA-N 0.000 claims 1
- UOAXMMISMWRAMK-SNVBAGLBSA-N C(=CCCCCCC)N[C@H](C)C(=O)O Chemical compound C(=CCCCCCC)N[C@H](C)C(=O)O UOAXMMISMWRAMK-SNVBAGLBSA-N 0.000 claims 1
- 239000004971 Cross linker Substances 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 108010069091 Dystrophin Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023014917A JP2023055874A (ja) | 2015-12-21 | 2023-02-02 | ステープルまたはステッチペプチドに複合された生物活性化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1522548.5 | 2015-12-21 | ||
| GB1522548.5A GB2545898B (en) | 2015-12-21 | 2015-12-21 | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| PCT/GB2016/054028 WO2017109494A1 (en) | 2015-12-21 | 2016-12-21 | Biologically active compound conjugated to a stapled or stitched peptide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023014917A Division JP2023055874A (ja) | 2015-12-21 | 2023-02-02 | ステープルまたはステッチペプチドに複合された生物活性化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019508481A JP2019508481A (ja) | 2019-03-28 |
| JP2019508481A5 true JP2019508481A5 (enExample) | 2020-02-13 |
| JPWO2017109494A5 JPWO2017109494A5 (enExample) | 2022-06-16 |
Family
ID=55311362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550872A Pending JP2019508481A (ja) | 2015-12-21 | 2016-12-21 | ステープルまたはステッチペプチドに複合された生物活性化合物 |
| JP2023014917A Pending JP2023055874A (ja) | 2015-12-21 | 2023-02-02 | ステープルまたはステッチペプチドに複合された生物活性化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023014917A Pending JP2023055874A (ja) | 2015-12-21 | 2023-02-02 | ステープルまたはステッチペプチドに複合された生物活性化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11541124B2 (enExample) |
| EP (1) | EP3393520A1 (enExample) |
| JP (2) | JP2019508481A (enExample) |
| KR (1) | KR20180091920A (enExample) |
| CN (1) | CN108472385A (enExample) |
| AU (1) | AU2016375869B2 (enExample) |
| BR (1) | BR112018012641A2 (enExample) |
| CA (1) | CA3007910A1 (enExample) |
| GB (1) | GB2545898B (enExample) |
| WO (1) | WO2017109494A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| SG11201906200WA (en) | 2017-01-06 | 2019-08-27 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| US11339192B2 (en) | 2017-10-04 | 2022-05-24 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitors |
| CA3080617A1 (en) | 2017-10-27 | 2019-05-02 | Ohio State Innovation Foundation | Polypeptide conjugates for intracellular delivery of stapled peptides |
| WO2019148195A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Cyclic peptidyl inhibitors of cal-pdz binding domain |
| AU2019218786B2 (en) * | 2018-02-07 | 2024-05-02 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| WO2020047399A1 (en) * | 2018-08-31 | 2020-03-05 | Massachusetts Institute Of Technology | Ionizable lipidoids and their uses |
| CA3135115A1 (en) | 2019-04-18 | 2020-10-22 | Dana-Farber Cancer Institute, Inc. | Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides |
| KR102499670B1 (ko) * | 2019-06-17 | 2023-02-20 | 고려대학교 산학협력단 | 라이신 치환을 포함하는 Romo1 유래 항균 펩타이드 및 그 변이체 |
| KR102521182B1 (ko) * | 2020-11-06 | 2023-04-12 | 서울대학교산학협력단 | 결핵균 독소-항독소 시스템을 표적으로 하는 항균 스테이플 펩타이드 및 이의 용도 |
| WO2024069229A2 (en) | 2022-08-03 | 2024-04-04 | Sutura Therapeutics Ltd | Biologically active compounds |
| WO2025027389A1 (en) | 2023-08-03 | 2025-02-06 | Sutura Therapeutics Limited | Biologically active compounds comprising a stapled or stitched peptide |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3856406T2 (de) * | 1987-10-28 | 2000-10-19 | Howard Florey Institute Of Experimental Physiology And Medicine, Parkville | Oligonucleotid-polyamid konjugate |
| WO2009008725A2 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| NZ584793A (en) * | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2285970A4 (en) * | 2008-06-03 | 2011-10-12 | Aileron Therapeutics Inc | COMPOSITIONS AND METHODS FOR REINFORCING THE CELL TRANSPORT OF BIOMOLECULES |
| IL313162A (en) | 2008-10-24 | 2024-07-01 | Sarepta Therapeutics Inc | Antisense compounds for inducing axon termination and preparations containing them for the treatment of muscular dystrophy |
| EP2421971B1 (en) * | 2009-04-24 | 2016-07-06 | BioMarin Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
| CA2768299C (en) * | 2009-07-13 | 2018-03-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| WO2011111874A1 (ja) | 2010-03-11 | 2011-09-15 | 独立行政法人理化学研究所 | 細胞膜透過性ダンベル型rnaおよびその製造方法 |
| EP3231446B1 (en) * | 2010-04-19 | 2026-01-07 | Palomo Limited | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| KR102229650B1 (ko) | 2011-05-05 | 2021-03-19 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
| CN103998458B (zh) | 2011-08-30 | 2018-10-09 | 医学研究理事会 | 具有中央疏水域的细胞穿透肽 |
| CN103121959B (zh) | 2011-11-21 | 2016-09-21 | 昆山市工业技术研究院小核酸生物技术研究所有限责任公司 | 化合物和核酸复合分子与核酸复合物及其制备方法和应用 |
| WO2013150338A1 (en) * | 2012-04-04 | 2013-10-10 | Centre National De La Recherche Scientifique | Stapled cell penetrating peptides for intracellular delivery of molecules |
| WO2014053879A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP2911697A1 (en) * | 2012-10-26 | 2015-09-02 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to cell types |
| CN103626850B (zh) | 2013-04-03 | 2015-08-26 | 安徽省新星药物开发有限责任公司 | 具有细胞穿透功能的多肽及其在药物递送中的用途 |
| MA42134A (fr) * | 2015-05-19 | 2018-03-28 | Sarepta Therapeutics Inc | Conjugués peptides/oligonucléotides |
| MX384213B (es) | 2015-07-15 | 2025-03-14 | Protagonist Therapeutics Inc | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias. |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| GB2563875B (en) | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
-
2015
- 2015-12-21 GB GB1522548.5A patent/GB2545898B/en not_active Expired - Fee Related
-
2016
- 2016-12-21 WO PCT/GB2016/054028 patent/WO2017109494A1/en not_active Ceased
- 2016-12-21 BR BR112018012641A patent/BR112018012641A2/pt active Search and Examination
- 2016-12-21 JP JP2018550872A patent/JP2019508481A/ja active Pending
- 2016-12-21 EP EP16822244.6A patent/EP3393520A1/en not_active Withdrawn
- 2016-12-21 KR KR1020187020172A patent/KR20180091920A/ko active Pending
- 2016-12-21 US US16/061,548 patent/US11541124B2/en active Active
- 2016-12-21 AU AU2016375869A patent/AU2016375869B2/en not_active Ceased
- 2016-12-21 CN CN201680073127.3A patent/CN108472385A/zh active Pending
- 2016-12-21 CA CA3007910A patent/CA3007910A1/en active Pending
-
2022
- 2022-12-27 US US18/088,933 patent/US11944688B2/en active Active
-
2023
- 2023-02-02 JP JP2023014917A patent/JP2023055874A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508481A5 (enExample) | ||
| JP2023055874A (ja) | ステープルまたはステッチペプチドに複合された生物活性化合物 | |
| CN103998458B (zh) | 具有中央疏水域的细胞穿透肽 | |
| US12465646B2 (en) | Linkers | |
| JP2015529073A5 (enExample) | ||
| JP2015501817A5 (enExample) | ||
| JP2015518825A5 (enExample) | ||
| JP2020525462A5 (ja) | 改善された薬物送達のためのステープルされた又はステッチされたペプチドを含む化合物 | |
| JP2023126866A (ja) | 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物 | |
| JP2022543320A (ja) | 複合体及びその使用 | |
| US12472264B2 (en) | Cell-penetrating peptides | |
| JP2017523781A5 (enExample) | ||
| JPWO2017109494A5 (enExample) | ||
| CN114392358A (zh) | 一种肿瘤靶向的核酸适体药物偶连物 | |
| Song et al. | New Transferrin Receptor‐Targeting Conjugate Effectively Delivers DNA to Mouse Brain | |
| EP2741783A1 (de) | Polyanion-nanokomplexe für therapeutische anwendungen | |
| JPWO2019002875A5 (enExample) | ||
| GB2580569A (en) | Improvements in drug delivery | |
| DE102017204850A1 (de) | HSA-Konjugat | |
| GB2574525A (en) | Improvements in drug delivery | |
| JP2021038184A (ja) | 難水溶性薬物の複合体及びその製造方法 |